Special Issue "Heterocyclic and Medicinal Chemistry"

Quicklinks

A special issue of Molecules (ISSN 1420-3049).

Deadline for manuscript submissions: 31 May 2014

Special Issue Editor

Guest Editor
Prof. Dr. Richard A. Bunce
Department of Chemistry, Oklahoma State University, Stillwater, Oklahoma 74078-3071, USA
Website: http://chemistry.okstate.edu/faculty/32-faculty/info/101-bunce
E-Mail: rab@okstate.edu
Interests: heterocycles; antibacterial agents; anticancer agents; enzyme inhibitors; medicinal chemistry; drug discovery; drug development; synthetic methodology

Special Issue Information

Dear Colleagues,

The development of new medicinal agents is critical to maintaining a high quality of life as well as a healthy and productive society. As established pharmaceuticals lose potency due to drug resistance, it is imperative that new treatments be developed to combat more resilient pathogens as well as cancer cell proliferation without harming patients. Heterocycles are the key to biological activity in many small molecule drugs due to their ability to hydrogen bond, alter polarity and modulate lipophilicity at specific sites in the pathogen or host with the overall effect of inhibiting the biological processes that lead to programed progression of diseases. These subunits thus have the ability to improve pharmacological, pharmacokinetic, toxicological and physicochemical properties of compounds, making them more effective in alleviating a variety of afflictions. In this Special Issue of Molecules, entitled “Heterocyclic and Medicinal Chemistry”, I invite manuscript submissions that focus on agents having potential for the treatment of diseases and conditions affecting human and animal health. Original research articles or reviews that discuss the design, synthesis, development and mode of action of drug candidates incorporating heterocyclic subunits are particularly welcome.

Dr. Richard A. Bunce
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).


Keywords

  • heterocycle synthesis
  • drug design
  • drug synthesis
  • drug discovery
  • antibacterial agents
  • anticancer agents
  • antifungal agents
  • anti-inflammatory agents
  • antimicrobial agents
  • antiviral agents
  • enzyme inhibition

Published Papers (2 papers)

Molecules 2014, 19(3), 3231-3246; doi:10.3390/molecules19033231
Received: 11 January 2014; in revised form: 8 March 2014 / Accepted: 10 March 2014 / Published: 17 March 2014
Show/Hide Abstract | Download PDF Full-text (528 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Molecules 2014, 19(1), 896-910; doi:10.3390/molecules19010896
Received: 12 November 2013; in revised form: 6 January 2014 / Accepted: 8 January 2014 / Published: 14 January 2014
Show/Hide Abstract | Download PDF Full-text (687 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files
abstract graphic

Last update: 23 December 2013

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert